As of 05 Nov 2026 16:37 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2022/061 (11 Jul 2022): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Buserelin (Suprefact®) 5.5mg/5.5ml solution for injection vialsaffected product · inferred from phrasing | Out of stock, as stated⚠ the source line states more than one status — first stated shown | mid-August 2022precision: mid-month · window end 20 Aug 2022, derived from “mid-August 2022” | notice of 11 Jul 2022 |
| Buserelin (Suprecur®)150microgram/dose nasal sprayaffected product · inferred from phrasing | Out of stock, as stated⚠ the source line states more than one status — first stated shown | late-December 2022precision: late in the month · window end 31 Dec 2022, derived from “late-December 2022” | notice of 11 Jul 2022 |
| Nafarelin (Synarel®) 200microgram/dose nasal spraynamed by the source as remaining available · inferred from phrasing · its own page → | Stated as available; cannot support an uplift in demand⚠ the source line states more than one status — first stated shown | — not stated for this line | notice of 11 Jul 2022 |
| Alternative gonadotrophin-releasing hormone (GnRH) analogues (parenteral formulations)class-level statement by the source, not a named product · inferred from phrasing | Stated as available | — not stated for this line | notice of 11 Jul 2022 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
- Nafarelin (Synarel®) 200microgram/dose nasal spray — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Suprefact
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Sep 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
One supply notification on record, 11 Jul 2022. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 11 Jul 2022 | Medicine Supply Notification: Suprefact and Suprecur | Supply notification | Tier 2 | MSN/2022/061 |
Also recorded under
No other name appears in this medicine's notice titles. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
No NHS Scotland Medicine Supply Alert Notice on record matches this name. Scotland is a separate record (all Scotland alerts); absence here is not a statement about supply in Scotland.